Motus GI (NASDAQ:MOTS – Get Rating) and Vivos (OTCMKTS:RDGL – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.
Volatility and Risk
Motus GI has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Vivos has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.
Earnings and Valuation
This table compares Motus GI and Vivos’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Motus GI||$390,000.00||22.75||-$19.03 million||($7.66)||-0.39|
This is a breakdown of current recommendations and price targets for Motus GI and Vivos, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Motus GI presently has a consensus price target of $11.50, suggesting a potential upside of 288.51%. Given Motus GI’s higher possible upside, analysts plainly believe Motus GI is more favorable than Vivos.
This table compares Motus GI and Vivos’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
0.0% of Vivos shares are owned by institutional investors. 8.8% of Motus GI shares are owned by insiders. Comparatively, 18.5% of Vivos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Vivos beats Motus GI on 6 of the 11 factors compared between the two stocks.
About Motus GI
Motus GI Holdings, Inc., a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.